Structural neuroimaging across early-stage psychosis: Aberrations in neurobiological trajectories and implications for the staging model

CF Bartholomeusz; VL Cropley; C Wannan; M Di Biase; PD McGorry; C Pantelis

Journal article

Structural neuroimaging across early-stage psychosis: Aberrations in neurobiological trajectories and implications for the staging model

CF Bartholomeusz, VL Cropley, C Wannan, M Di Biase, PD McGorry, C Pantelis

Australian and New Zealand Journal of Psychiatry | Published : 2017

DOI: 10.1177/0004867416670522

Abstract

Objective: This review critically examines the structural neuroimaging evidence in psychotic illness, with a focus on longitudinal imaging across the first-episode psychosis and ultra-high-risk of psychosis illness stages. Methods: A thorough search of the literature involving specifically longitudinal neuroimaging in early illness stages of psychosis was conducted. The evidence supporting abnormalities in brain morphology and altered neurodevelopmental trajectories is discussed in the context of a clinical staging model. Results: In general, grey matter (and, to a lesser extent, white matter) declines across multiple frontal, temporal (especially superior regions), insular and parietal regi..

View full abstract

University of Melbourne Researchers

Cali Bartholomeusz Author

Vanessa Cropley Author

Cassandra Wannan Author

Maria Di Biase Author

Related Projects (3)

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

Using brain imaging to distinguish amongst subtypes of schizophrenia: An investigation of brain muscarinic receptors.

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC) Senior Principal Research Fellowship

Awarded by Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award (US)

Awarded by NHMRC

Funding Acknowledgements

C.P. was supported by a National Health and Medical Research Council of Australia (NHMRC) Senior Principal Research Fellowship (628386 and 1105825) and a Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award (US; Grant ID: 18722). P.D.M. currently receives research support from NHMRC and the Colonial Foundation. He has also received grant funding from NARSAD and unrestricted research funding from Astra Zeneca, Eli Lilly, Janssen-Cilag, Pfizer and Novartis, as well as honoraria for educational activities with Astra Zeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol Myer Squibb, Roche and the Lundbeck Institute. V.C. was supported by an NHMRC Training Fellowship (ID: 628880) and University of Melbourne Fellowship. M.D.B. was supported by the Rotary Health Ian Scott PhD Scholarship in Mental Health. C.W. was supported by a Cooperative Research Centres for Mental Health Scholarship.